#Global #Business Line : Strategic #Investor Interest – #BrainImplant

The investor base reflects a broader shift toward #funding high-risk, science-driven startups. These firms are betting on long-term breakthroughs rather than short-term returns, particularly in areas where #technological #convergence—such as #biology and #computing—creates new #markets.

Global Business Line : Strong #Growth and #Funding Trends – #BrainImplant

The #global #BCI market is projected to surpass $6–8 billion by 2030, growing at a #CAGR of over 15%. #Venture funding has #accelerated alongside this growth. Companies like #Neuralink and #Synchron have #attracted #substantial capital, reflecting increasing #investor #confidence in #neurotechnology as a long-term #opportunity.

#Global #Business Line : #Capital Raised and #Investor Backing – #BrainImplant

Science Corp. has raised more than $160 million since its founding in 2021. The company’s #funding rounds have #attracted #prominent venture firms, including Khosla #Ventures and #Founders #Fund, both known for backing deep-tech and life sciences ventures.